Dr. Burke has experience in both clinical medicine and research. Before becoming a specialist in Hematology and Oncology, Dr. Burke worked for several years as a primary care physician in a rural area of upstate New York. In this location, she served in several leadership positions including: Executive Committee of the Cayuga County Medical Society, Medical Director of several homes for learning disabled adults (for State of NY), and Medical Director of CHAD (Alcohol and Drug Treatment home), Medical Director for NY Bottling Company, and Chair of the Nursing Committee at Auburn Memorial Hospital. In her private practice, she had a CAP-certified laboratory, pulmonary function lab and EKG monitoring program. Prior to entering practice and subsequent to this, Dr. Burke worked as an emergency room physician in both rural areas and major trauma centers. Her past certifications have included ACLS (Advanced Cardiac Life Support), ATLS (Advanced Trauma Life Support), and APLS (Advanced Pediatric Life Support).
In 1990, she left practice to pursue a long-term plan to work in basic science. For two years, she worked at NIDDK at the NIH studying the switch from fetal to adult hemoglobin, with an emphasis on sickle cell anemia. Subsequently, she worked at the Laboratory of Biochemistry at the National Cancer Institute as the recipient of a Biotechnology Fellowship Award. In these locations she had the opportunity to learn from top scientists, including members of the National Academy of Sciences and authors of papers in major journals such as Nature, Cell, and Blood.
After fellowship, Dr. Burke worked at the US Food and Drug Administration as a Medical Officer, where she was actively involved in the regulatory process for both IND (Investigational New Drugs) and NDA (New Drug Applications) in Critical Care and Anesthesia. In 1996, she received a fellowship in leukemia research and studied under Dr. Nancy Speck at Dartmouth. From there, Dr. Burke entered a fellowship in Hematology and Oncology. During her fellowship she participated in the Phase I program at Dartmouth Hitchcock Medical.
Dr. Burke has provided mentorship to several students from high school students to graduate students. Several of her students have won national, state and local awards.
Undergraduate: Macalester College: BA Chemistry
Undergraduate: University of Minnesota: BS Microbiology
Medical School: University of Minnesota Medical School MD
Residency: University of Alabama at Birmingham: Internal Medicine
Fellowship: Dartmouth Hitchcock Medical Center: Hematology and Oncology
Hematology - Board Certified 2001; Recertified 2011 (Expires 2021)
Oncology - Board Certified 2001; Recertified 2011 (Expires 2021)
Internal Medicine - Board Certified 1982, Voluntary Recertification 2011
Voluntary Recertification 2011-2021
Interests: Signal Transduction; Translational Research; Expanded Access; Phase I/II/III trials; Phase IV trials in special populations
Education in Clinical Trial Design/Mentorship
American Society of Clinical Oncology (ASCO)
American Association for Cancer Research (AACROncology)
American Society of Hematology (ASH)
American College of Physicians (ACP)
European Society for Medical Oncology (ESMO)
Peer reviewer in last several years includes the following professional journals: Annals of Internal Medicine, Cancer, Cancer Investigation, Journal of Clinical Oncology, Chest, Journal of Lipid Research, Leukemia and Lymphoma, Journal of Clinical Oncology
Member of ECU-UNC Lineberger Protocol Review Committee, 2009 to present
Member of PCMH hospital Ethics Committee: 2003 to 2009
Honors and Awards:
National Merit finalist scholarship, Macalester College
Finalist for Robert Wood Johnson award for outstanding Freshman, Macalester College, 1970
Pillsbury scholarship, Macalester College, 1972
Student representative, Board of Directors, University of Minnesota Hospitals, 1978
Finance Committee of the Board of Directors, 1978
National Research Service Award, 1990, 1991, NIDDK
Biotechnology Fellow Award, 1992, 1993, 1994, NCI
Molecular model featured on cover of Journal of Molecular Biology, October, 1995
Performance award, FDA, November, 1996
Florence A. Carter Award for research in leukemia, July 1997- July 1998
Young Investigator Award, Cancer and Leukemia Group B (CALGB), April, 2000
Pfizer Clinical Research Grant 2002 to present
NCCC Friends fellowship award, Dartmouth, 2000 to 2001
Cancer Research Award, Auxiliary of VFW, October 2002
Physician Scientist Award, ECU, December 2002 to 2005
Professional Publications (Most Recent First)
Burke LP. Cancer Cooperative Groups as a Model for Comparative Effectiveness Research (Submitted)
Katz A, Burke LP, Brinson. Demographic characterization of patients with large breast-cancer: an under-recognized public health problem. J Health Care Poor Underserved. 2010; 21(2): 666-79.
Burke LP; Kukoly C,. Statins induce lethal effects in acute myeloblastic leukemia cells within 72 hours. Leukemia and Lymphoma. (2008). 49:2, 322-330.
Burke LP, LD Lewis and RP Perez.. Ubiquinone Does Not Rescue Acute Myeloid Leukemia Cells from Growth Inhibition by Lovastatin. Leukemia. (2003) 17:267-8.
Burke LP. Review of literature on Clonidine. FDA. 1996. Confidential, peer-reviewed publication accepted by CDER, FDA, 1996
Burke LP, and Mortin M. Transcriptional Competition and Homeosis. Biochemical Genetics (1996) 34:45-59
DeBellis MD, Burke LP, Trickett PK, Putnam FW. Antinuclear antibodies and thyroid function in sexually abused girls. J of Traumatic Stress (1996) 9(2):369-378
Kim WJ, Burke LP, Mortin M. Modeling of Interacting Mutations of RNA Polymerase II on the Tertiary Structure of DNA Polymerase I predicts functional interactions J Mol Biol 1994 Nov 18;244(1):13_22. (Model featured on cover)
De Bellis MD, Chrousos GP, Dorn LD, Burke LP, Helmers K, Kling MA, Trickett PK, Putnam FW. Hypothalamic-Pituitary-Adrenal Axis Dysregulation in Sexually Abused Girls. Clinical Endocrinology and Metabolism October, 1993.
Fibach E., Burke LP, Schechter A.N., Noguchi C.T. & Rodgers G.P.
Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or -Thalassemia. Blood 81, 1630-1635, 1993.
Burke LP, in: Irish, DP. “Reflections by Professional Practitioners,” in :Ethnic Variations in Dying, Death, and Grief (Irish DP, Lundquist KF, Nelsen VJ, eds), Taylor and Francis, 1993, pages 167-170.
Rank BH, Gay C, Burke LP, Wright K, Nollet DJ, Blomberg DL. (1980)
“Post-transfusion Purpura as a Gynecologic Complication”. Obstet Gynecol 55(Suppl): 725-755, 1980.
Cohn JN and Burke LP. Nitroprusside. Annals of Internal Medicine 92(5): 752-757, 1979.
Burke LP and Swart K. Study guide for General Biology, University of Minnesota, Extension Division, 1976.
Burke L. Clinical Trial Abstract (Submitted ASCO 2012)
J. M. Eggar, C. S. Lea, L. S. Bellin, R. E. Raab, J. H. Wong, L. P. Burke. A pilot study of the decision-making process of seeking medical care in women diagnosed with large breast tumors. J Clin Oncol 29, 2011 (suppl 27; abstr 237)
M. T. Weed, A. Rosenberg, L. Burke, M. Haque, P. Vos, A. Aravapalli, M. Brinson. Frequency of diagnosis of Medicaid patients with colorectal cancer by screening colonoscopy – at the Gastrointestinal Cancers Symposium 2008. Also presented at Digestive Diseases; 2008.
M. T. Weed, A. Rosenberg, L. Burke, M. Haque, P. Vos, A. Aravapalli, M. Brinson. Medicaid patients with colorectal cancer are rarely diagnosed by screening colonoscopy. GI ASCO January 2008, Abstract # 396.
Rosenberg A, Burke L, Vos P, Liles, D. Self-Exam is the Most Common Method of Breast Cancer Identification. ASCO; poster presented 2007 meeting Abstract #1543
Huafeng Ding, Jun Q. Lu, R. Scott Brock, Lillian Burke, Douglas A. Weidner, Thomas J. McConnell, Xin-Hua Hu. Determination of Intracellular Distributions of Refractive Index of B-cells and HL60 cells at 442, 633 and 850nm. Oral presentation at the Frontiers in Optics 2006/Laser Science XXII conferences in Rochester, New York. October 8-12, 2006.
Rosenberg A; Burke L; Vos P; Brinson M. Factors Predicting Tumor Size at Presentation in Breast Cancer Patients. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 10609
Huafeng Ding, Jun Q. Lu, R. Scott Brock, Kenneth M. Jacobs, Thomas J. McConnell, Lillian Burke, Xin-Hua Hu* , “Angle-resolved Mueller Matrix Study of Light Scattering by B-Cells and HL-60 Cells at Three Wavelengths of 442, 633 and 850nm”, OSA Biomedical Optics conference, paper ME73, March 19-22, 2006, Miami, Florida.
Burke, LP. Letter to the Editor Published 1.2006; Daily Reflector; Insurance Problems of Oncology Patients; 1.2006.
Burke, LP. Renal Cancer: New and Old Options in Therapy. Spring 2005; Oncology Tumor Board Talk and Case Review.
Burke, LP. CNS Lymphoma: Is Radiation Always Needed? Controversies in Hematology (Duke University Conference); February 4, 2005.
Ramasamy D, McCubrey JA, Kukoly C, Burke L, Shelton JG, Steelman LS, Chintalgattu V, Katwa L, Li J. Akt or Bdl-2 overexpression did not influence the IC50 of liver stellate cells in the presence of HMG CoA reductase inhibitors: Potential therapeutic use of statins in the treatment of drug resistant cells. The Liver Meeting October 2004; Boston MA.
Burke, LP. Evaluation and Management of Pain in the Cancer Patient. Palliative Care Conference. Spring, 2004. (Invited Speaker).
Burke, LP, Allen D, Kukoly C. Both Farnesylpyrophosphate (FPP) And Geranylgeranylpyrophosphate (GGPP) Rescue Prenylation In The Presence Of Statins, But Only GGPP Rescues Cell Viability. Proceedings of the AACR, Volume 45, 2025; March 2004.
Burke, LP; Molecular Oncology, Medicine Grand Rounds, April, 2003.
Research Aspects of Molecular Oncology, Microbiology and Immunology, April 2003.
Burke, LP; Biochemical and Clinical studies of Statins as Anticancer Therapy, Biochemistry Dept February, 2003.
Burke, LP; Thrombotic Thrombocytopenic Purpura; Interdisciplinary Tumor Board; February 2003.
Burke, LP; Lewis L.; Perez RP. Ubiquinone does not rescue acute myeloid leukemia cells from lovastatin effects on cellular proliferation, myeloid differentiation, or prenylation [abstract #500]. Blood. 2001; 98 (11):119a.
Burke LP, Ray Perez, Christopher Lowrey, and Lionel Lewis. Atorvastatin as a Signal Transduction Inhibitor for Treatment of Acute Myelogenous Leukemia. Awarded CALGB Young Investigator Award April 2000. FDA approved January, 2001. IRB approved, first patient admitted April, 2001.
Burke LP (PI), James Leiter, and the Pleural Effusion Study Group. Treatment of Malignant Pleural Effusion: Comparison of Two Methods of Chest Tube Drainage with Talc Pleurodesis. Approved by Dartmouth-Hitchcock Medical Center Institutional Review Board, September, 2000; Closed due to FDA removal of talc from market.
Burke LP, Wright C, Lockwood P, Tyler T, Bedford R. Evaluation of hypoventilation/hypoxia in clinical trials. Scientific Rounds, CDER, FDA, February 14, 1996.
Burke, LP and Mortin M. Mutations in RNA Polymerase II cause the UBX-like phenotype by an effect occurring prior to the elongation step in transcription. (abstract) J Cellular Biochemistry February, 1994.
Kim WJ, Burke LP, Mortin M. Homology between RNA Polymerase II and DNA Polymerase I. Gordon Conference, June, 1993.
DeBellis MD, Dorn L, Burke LP, et al. Suppression of ACTH/Cortisol Axis in Adolescents with a History of Sexual Abuse. (Abstract) American Academy of Child and Adolescent Psychiatry. October, 1992.
Burke LP, DeBellis MD, et al. Somatization in Children and Adolescents with a History of Sexual Abuse. (abstract) American Academy of Child and Adolescent Psychiatry. October, 1992 meeting.
Burke LP, Alyson G. Wilson, Alan N. Schechter, and Constance T. Noguchi. Hydroxyurea-Induced Enhancement of Fetal Haemoglobin in Erythroid Progenitor Cells: Cellular Kinetics and Haemoglobin Production.
Burke LP, Fibach, E; Rodgers, G; Schechter, AN; Noguchi, CT; Fetal Hemoglobin is increased in a Primary Erythroid Liquid Culture System. (Abstract) American Federation of Clinical Research, May, 1992.
Burke LP. Medical libraries (letter) NY State J of Med, Aug 1990.
Burke LP, for Medical Society, State of New York. Testimony on toy guns. NY State Senate, 1988. (Senator Christopher Menges) Center and wrote a clinical trial grant funded by the NIH CTEP Rapid Trials program.